CTRI/2021/11/037994招募中3 期
A Prospective, Multi-center, Randomized, Open-Label, Parallel-group, Active-controlled, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Insulin Glargine 100 IU/mL Injection of M.J. Biopharm Private Limited with Lantus�® (Insulin Glargine Injection) 100 units/mL in the Treatment of Patients Diagnosed withType 2 Diabetes Mellitus.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing to provide the written informed consent
- •2. Male and female adult patients, at an age of 18 to 65 years, both inclusive
- •3. Type 2 diabetes mellitus based on the disease diagnostic criteria provided by World Health Organization (WHO) guidelines
- •4. Duration of diabetes mellitus greater than or equal to 12 months
- •5. Receiving 2 or more Oral Antidiabetic Medicinal products (OAMs) at stable doses for 12 weeks prior to screening, with or without LantusÃ?®. The use and dose of oral agents in combination with insulin had to be in accordance with the product label. If on Lantus, must be on once daily stable dose (Ã?±15% variation in dose) for at least 3 months prior to screening.
- •6. Haemoglobin level of ââ?°Â¥9.0 g/dL
- •7. Glycosylated haemoglobin (HbA1c) between 7.5% and 10.5%.
- •8. Body mass index (BMI) between 18 and 38 kilograms/meter square (kg/mÃ?²)
- •9. Stable weight, with no significant and appreciable loss or gain, in the 3 months prior to screening; this information will be obtained by patient interview during medical history
- •10. Female patients of childbearing potential, in addition to having a negative serum pregnancy test, must be willing to use a reliable means of contraception (other than hormonal contraceptives) e.g. barrier method (diaphragm, condom, etc.), surgical sterilization (at least 6 months prior to study drug administration) or abstinence for the duration of the study. Patients should use the reliable method of contraception from screening, during study and up to and for at least two weeks after treatment discontinuation
- •11. Ability and willingness to administer study medication daily as injections to abdomen, thigh, or upper arm
- •12. As determined by the investigator, the patient should be capable and willing to do the following:
- •a. Perform self-monitored blood glucose (SMBG)
- •b. Complete Subject diaries as instructed
- •c. Be receptive to diabetes education
- •d. Be able and willing to adhere to the protocol requirements
排除标准
- •1. Type 1 diabetes mellitus
- •2. Used any other insulin except LantusÃ?® within the previous 30 days. Have been on LantusÃ?® more than once daily within the previous 30 days.
- •3. Exposed to a biosimilar insulin glargine within the previous 90 days
- •4. History of taking basal bolus therapy or, in the investigatorââ?¬•s opinion, required mealtime insulin to achieve target control
- •5. Type 2 Diabetes patients with metabolic complications such as diabetic ketoacidosis within 6 months of screening visit
- •6. Used glucagon-like peptide 1 (GLP-1) agonist within the previous 90 days
- •7. Used thiazolidinediones (TZDs) within the previous 90 days
- •8. Excessive insulin resistance at study entry (total insulin dose ââ?°Â¥1.5 U/kg)
- •9. More than one episode of severe hypoglycemia defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, within 6 months prior to study entry
- •10. Known hypersensitivity or allergy to insulin glargine or its excipients OR history of significant allergic drug reactions
- •11. Receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy at pharmacological doses (excluding topical, intra-articular, intra-ocular, or inhalational preparations and physiologic replacement doses for adrenal deficiency) or had received such therapy within 4 weeks prior to screening
- •12. Inadequately treated hypertension (systolic ââ?°Â¥150 mm Hg or diastolic ââ?°Â¥100 mm Hg)
- •13. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of < 60 mL/min/1.73 m2 at screening.
- •14. Evidence of hypokalemia (serum potassium < 3.5 mmol/L at screening)
- •15. Known case of chronic liver disease or hepatic impairment, defined as any serum liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase) ââ?°Â¥ 2.5 times ULN at screening
- •16. Congestive heart failure (New York Heart Association [NYHA] class III & class IV), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism or any other established major cardiovascular disease prior to screening
- •17. History of or ongoing cardiac dysrhythmias requiring treatment, such as uncontrolled atrial fibrillation
- •18. Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardize patientââ?¬•s safety or compliance with the protocol
- •19. Active cancer or personal history of cancer within previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ)
- •20. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness, or positive HIV seropositivity at screening
- •21. Known active or chronic hepatitis B or hepatitis C infection, or Hepatitis B and Hepatitis C seropositivity at screening, if not related to vaccination
- •22. Blood transfusion or severe blood loss within 3 months prior to screening, or known haemoglobinopathy, hemolytic anemia, or sickle cell anemia
- •23. Prohibited medications which cannot be discontinued at randomization or anticipated initiation or change in concomitant medications known to affect glucose metabolism
- •24. Breastfeeding, pregnant,
研究者
相似试验
尚未招募
3 期
A study to evaluate the Safety and Effectiveness of Tofacitinib Gel versus Minoxidil Solution in Treatment of Adult Male Patients with Androgenetic Alopecia.CTRI/2022/09/045412MACLEODS PHARMACEUTICALS LTD
尚未招募
4 期
To Assess the Safety and Efficacy of Imusil tablet in Treatment of Adult Subjects with mild COVID-19CTRI/2022/02/040687Glowderma Lab Private Limited
尚未招募
不适用
Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19Corona Virus COVID-19PACTR202012892855610Oncotelic Incorporated120
招募中
4 期
Phase IV study to evaluate the safety and efficacy of Artemisinin- a herbal supplement on COVID-19 subjectsCTRI/2020/09/028044Windlas Biotech Private Limited
进行中（未招募）
1 期
Evaluation of Equine antibody treatment in patient with COVID 19 infectioCTRI/2021/02/031566Bharat Serums and Vaccines ltd